BIO Requested

No. 23-768

Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., et al.

from the United States Court of Appeals for the Federal Circuit

See other cases from the Federal Circuit.

Docket Entries

Brief amici curiae of Professor Christopher M. Turoski and The National Association of Patent Practitioners filed.

Response Requested. (Due March 18, 2024)

Brief amici curiae of American Council of the Blind, Blinded Veterans Association, and PRISMS filed.

Brief amici curiae of Salix Pharmaceuticals, Inc. and Ocular Therapeutix, Inc. filed. (Distributed)

DISTRIBUTED for Conference of 2/23/2024.

Waiver of right of respondents Apotex Inc. and Apotex Corp. to respond filed.

Waiver of right of respondent Teva Pharmaceuticals USA, Inc. to respond filed.

Petition for a writ of certiorari filed. (Response due February 16, 2024)

Application (23A344) granted by The Chief Justice extending the time to file until January 12, 2024.

Application (23A344) to extend the time to file a petition for a writ of certiorari from November 14, 2023 to January 12, 2024, submitted to The Chief Justice.

Parties

Vanda Pharmaceuticals Inc., Petitioner, represented by Paul Whitfield Hughes

Apotex Inc. and Apotex Corp., Respondent, represented by Aaron Scott Lukas

Teva Pharmaceuticals USA, Inc., Respondent, represented by John Christopher Rozendaal

Amici Curiae

American Council of the Blind, Blinded Veterans Association, and PRISMS, Amicus Curiae, represented by Mark Simon Davies

Professor Christopher M. Turoski and The National Association of Patent Practitioners, Amicus Curiae, represented by Ryan C. Morris

Salix Pharmaceuticals, Inc. and Ocular Therapeutix, Inc., Amicus Curiae, represented by Justin James Hasford

 
Last updated: April 22, 2024